FOR IMMEDIATE RELEASE
Dr. Peter B. Corr And Jean-Pierre Lehmann Appointed To Cibus Global Board Of Directors
San Diego, California (November 2, 2009) Cibus Global, a leading plant trait development company, today announced the appointment of two board members to reflect its growing international reach. Peter B. Corr, Ph.D., co-founder and general partner of Celtic Therapeutics Management and former Corporate Senior Vice President of Science and Technology at Pfizer, brings to the Cibus Board of Directors three decades of experience in molecular biology, research and product development. Jean-Pierre Lehmann is an international businessman who has spent more than 20 years overseeing private company investments in diversified industries.
“Bringing these two distinguished directors to Cibus Global’s board is another step toward expanding our footprint internationally,” said Stephen Evans-Freke, Chairman of Cibus Global. “We’re pleased to have Peter and Jean-Pierre’s expertise in scientific research, international development and financial strategy to help build Cibus Global into a significant player in global agri-business.”
“Cibus Global’s technology holds the potential to revolutionize product development programs in many areas,” said Dr. Corr. “This is a unique technology platform that, in my view, will incorporate traits in plants that will increase the availability of healthy food, feed and fiber, as well as provide a new source for energy. I am pleased to contribute my experience and knowledge to this endeavor.”
“The recent Mahkteshim-Agan agreement validates that Cibus Global’s environmentally-friendly technology has now come of age and will make significant changes to agriculture on a global scale, particularly in the European Union,” said Mr. Lehmann.
Peter B. Corr, Ph.D.
Before founding Celtic Therapeutics in 2007, Dr. Corr headed worldwide pharmaceutical research and development at Pfizer as senior vice president for Science and Technology. Previously, Dr. Corr was executive vice president, Pfizer Global Research & Development; and president, Worldwide Development. He also served as senior vice president, Discovery Research, at Monsanto/Searle and then, president of Pharmaceutical Research and Development at Warner Lambert/Parke Davis.
Dr. Corr also has an extensive academic background, spending two decades as a professor and researcher at Washington University in St. Louis. His research has been published in more than 160 scientific manuscripts.
Honors include induction into the Alpha Omega Alpha National Medical Honorary Society, an Established Investigator Award from the American Heart Association and a Research Career Development Award from the National Institutes of Health and Washington University Distinguished Faculty Award. Dr. Corr received his doctorate from Georgetown University School of Medicine.
Jean-Pierre Lehmann has been a private investor for the past 17 years, with a diversified portfolio in venture capital, as well as hotels and commercial and residential real estate in the United States. Prior to this, Mr. Lehmann resided in Geneva, Switzerland, where he managed portfolios for Morval Bank and its holding company. He previously oversaw a diversified holding company for Edmond de Rothschild.
Mr. Lehmann is a graduate of the Ecole des Hautes Etudes Commerciales in Paris and holds an M.B.A. from Harvard Business School; he was also an officer in the French Navy.
The Rosen Group
Notes to Editors:
About Cibus Global
Cibus Global (www.cibus.com) develops advantageous crop traits with far-reaching implications in agriculture, alternative energy and product development. Through its proprietary Rapid Trait Development System (RTDS), Cibus creates traits in a directed way with more precision than traditional breeding techniques and without the introduction of foreign genetic material. RTDS has proven itself in the laboratory with several different applications, as well as in initial field trials of Cibus’ first commercial crop, canola. Cibus’ products will be brought to market through a number of strategic partnerships.